We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sequenom and Iceland Genomics have entered into a research collaboration
to analyze Sequenom's proprietary panels of genetic markers associated with
breast and prostate cancer in Icelandic patient samples.
Santarus has announced that the primary objectives were met in its pivotal
pharmacokinetic/pharmacodynamic (PK/PD) clinical trials evaluating Zegerid
chewable tablets, 20 mg and 40 mg.
BioDelivery Sciences International (BDSI) has completed the clinical studies
required for its pending new drug application on Emezine, a buccal product
for the treatment of nausea and vomiting.
VIVUS has announced that clinical data from a Phase II study showed treatment
with the company's Testosterone MDTS, an investigational transdermal testosterone
spray, significantly increased the number of satisfactory sexual events in premenopausal
women with hypoactive sexual desire disorder (HSDD).
Forest Laboratories has initiated a Phase IIb/III study of desmoteplase, an
investigational novel plasminogen activator, or blood clot buster, for the treatment
of acute ischemic stroke.
Forest Laboratories, an international pharmaceutical manufacturer and marketer,
has posted its first set of data on the Forest Clinical Trial Registry.